US FDA Approves Sanofi's Wearable Injector Form of Blood Cancer Drug

The US FDA has approved Sarclisa Escena, Sanofi's wearable subcutaneous injector form of a multiple myeloma drug, replacing intravenous infusions and reducing patient time in infusion centres. The approval marks a regulatory win for Sanofi's new leadership as it diversifies beyond its dependency on asthma drug Dupixent. If you make wearable injectors, on-body delivery devices, or infusion centre software, Sanofi just proved the market will pay for convenience over IV. Every oncology drug with repeat dosing is now a candidate for this form factor—call the top 20 pharma companies this week.